FILTER
LATEST INTERVIEWS
Eduardo Cossio Chirinos
CEO, INCIMMET
INCIMMET speaks with GBR of its long experience as a contractor for mining projects in Peru and Colombia.
Robert Bloder
CHIEF BUSINESS OFFICER, ASCENDIA PHARMACEUTICALS
Ascendia Pharmaceuticals recounts the requirements to succeed in the CDMO space.
Jigar Raythatha
PRESIDENT & CEO, CONSTELLATION PHARMACEUTICALS
Constellation Pharmaceuticals explains its therapy for myelofibrosis and introduces its discovery engine.
Mike da Costa
CEO, GLOBAL MINING, MURRAY & ROBERTS (M&R)
Murray and Roberts in South Africa explains how technology is transforming mine development and shaft sinking.
Joe Walsh
MANAGING DIRECTOR, LEPIDICO
Lepidico is fast developing its integrated lithium operation, from its’ mine in Namibia to producing derived chemicals from plants to be built in UAE.
Bruce Anderson
BRUCE ANDERSON, CEO, 247SOLAR
247Solar explains to GBR why its unique Heat2Power turbines can provide clean, reliable and cheap energy to off-grid mines.
Marcelo Schumacker
COUNTRY DIVISION MANAGER, ABB CHILE
ABB explains why Chile provides an excellent market for its mining technologies.
Sandro Tavonatti
CEO, SIGDO KOPPERS INGENIERÍA Y CONSTRUCCIÓN (SKIC)
Sigdo Koppers Ingeniería y Construcción (SKIC) explains how it operates with Chile’s largest mines.
Florencio Castro & Alexandra Almenara
VP – PERU & VP ENVIRONMENT AND SUSTAINABILITY – SOUTH AMERICA, AUSENCO
Ausenco in Peru relates how it is developing the capacity to provide an integral service of engineering, environmental and social services to any project at any stage of their life cycle.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
